Related Experiment Video

Updated: Aug 11, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

Prevention of thromboembolic events in atrial fibrillation

B G Koefoed1, A L Gulløv, P Petersen

  • 1AFASAK 2 Study Center, Copenhagen, Denmark.

Thrombosis and Haemostasis
|July 1, 1997
PubMed

Insights

For patients with atrial fibrillation, effective stroke prevention requires specific oral anticoagulation intensities. Warfarin at an INR of 2.0-3.0 is recommended for high-risk individuals, while aspirin may suffice for younger patients without risk factors.

Area of Science:

  • Cardiology
  • Neurology
  • Pharmacology

Background:

  • Nonvalvular atrial fibrillation (AF) significantly increases stroke risk (4.5% annually).
  • Risk factors for stroke in AF include advanced age, prior stroke, diabetes, and hypertension.
  • Ischemic strokes in AF patients are often more severe than in those with normal sinus rhythm.

Purpose of the Study:

  • To review the efficacy of anticoagulation strategies for stroke prevention in nonvalvular atrial fibrillation.
  • To determine optimal oral anticoagulation intensity for high-risk AF patients.

Main Methods:

  • Review of clinical trials investigating warfarin and aspirin for stroke prevention in atrial fibrillation.
  • Analysis of data regarding the effectiveness of different oral anticoagulation intensities (INR levels).

Main Results:

  • Warfarin reduces stroke risk by 68%, while aspirin's efficacy is debated (18-44% reduction).
  • Low-intensity warfarin (INR < 2.0), alone or with aspirin, proved insufficient for stroke prevention in AF.
  • High-intensity warfarin (INR 2.0-3.0) is recommended for high-risk AF patients.

Conclusions:

  • Effective stroke prevention in nonvalvular atrial fibrillation necessitates appropriate oral anticoagulation intensity.
  • Warfarin at INR 2.0-3.0 is the recommended treatment for high-risk AF patients.
  • Aspirin 325 mg/day may be suitable for younger AF patients (<65) without additional risk factors.

More Related Videos

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation28:13

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation

Published on: February 26, 2013

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology10:46

Non-fluoroscopic Catheter Tracking for Fluoroscopy Reduction in Interventional Electrophysiology

Published on: May 26, 2015

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...